Product Description
Mechanisms of Action: CCR5 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acquired Immunodeficiency Syndrome|HIV Infections
Phase 2: Colorectal Cancer|HIV Infections|Acquired Immunodeficiency Syndrome
Phase 1: HIV Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03631407 |
MK-7690-046 | P2 |
Completed |
Colorectal Cancer |
2021-06-08 |
50% |
2022-06-09 |
Primary Endpoints |
NCT02356302 |
MTN-027 | P1 |
Completed |
HIV Infections |
2016-03-01 |
2019-03-20 |
Treatments |
|
2006-006417-32 |
VICTOR-E4 | P3 |
Terminated |
HIV Infections |
2010-10-26 |
2022-03-12 |
Treatments |
|
NCT00686829 |
P04100 | P2 |
Completed |
HIV Infections |
2010-10-21 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2006-003463-31 |
COVER | P3 |
Terminated |
Unknown |
2010-09-03 |
2025-07-05 |
Treatments |
|
NCT00705419 |
COVER | N/A |
Completed |
HIV Infections |
2010-09-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00766597 |
P1071 | P2 |
Completed |
HIV Infections |
2010-07-01 |
2019-03-18 |
Treatments |
|
NCT00551018 |
Study P04875 | P2 |
Completed |
HIV Infections |
2010-05-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00551330 |
VICTOR-E2; Protocol No. P05057 | P2 |
Completed |
Acquired Immunodeficiency Syndrome|HIV Infections |
2010-02-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2007-003133-16 |
P04875 | P2 |
Terminated |
HIV Infections |
2010-01-31 |
2022-03-12 |
Treatments |
|
NCT00474370 |
VICTOR-E4 | P3 |
Completed |
HIV Infections|Acquired Immunodeficiency Syndrome |
2009-08-24 |
2022-08-31 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
NCT00632073 |
Study P05241 | P1 |
Completed |
HIV Infections |
2009-07-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00523211 |
Study P04405AM5 | P3 |
Completed |
Acquired Immunodeficiency Syndrome|HIV Infections |
2009-06-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00243230 |
VICTOR-E1 | P2 |
Completed |
HIV Infections |
2007-10-19 |
2022-05-04 |
||
2005-001057-21 |
VICTOR-E1 | P2 |
Completed |
HIV Infections |
2007-04-16 |
2022-03-12 |
Treatments |
|
2005-001058-26 |
VICTOR-E2 | P3 |
Terminated |
HIV Infections |
2006-10-04 |
2022-03-12 |
Treatments |
|
NCT00082498 |
A5211 | P2 |
Completed |
HIV Infections |
2005-12-01 |
2024-05-07 |
Primary Endpoints|Treatments |
|
2005-001843-49 |
2005-001843-49 | P2 |
Terminated |
HIV Infections |
2005-11-15 |
2025-06-20 |
Treatments |
|
NCT00243568 |
VICTOR-E2 | P3 |
Withdrawn |
HIV Infections|Acquired Immunodeficiency Syndrome |
None |
2022-05-04 |
Treatments |